bioRxivNeurosciencePreprint
Disruption of CaMKII biomolecular condensation induces attention-deficit/hyperactivity disorder-like phenotypes
Yui SugiyamaiD, Chisato SuematsuiD, Risa YamadaiD, Atsuki GodaiD, Shogo MiyataiD, Tokiwa YamasakiiD, Ryuichi ShigemotoiD, Anjuli DijkmansiD, Danielle C. M. VeenmaiD, Shoji TakadaiD, Geeske M. van WoerdeniD, Yasunori HayashiiD, Takeo SaneyoshiiD
Abstract
CaMKII is a multifunctional kinase essential for synaptic plasticity and memory formation. While its canonical role involves enzymatic phosphorylation, recent evidence suggests CaMKII also functions through liquid-liquid phase separation (LLPS) with substrate proteins, including GluN2B-containing NMDA receptors. However, the physiological significance remains unclear. Here, we generated CaMKII subtype knock-in (KI) mice carrying a point mutation (I205K) in the hydrophobic pocket, a key interface required for LLPS. These mice exhibited a complete loss of structural long-term potentiation (sLTP) despite normal spine morphology, marked hyperactivity and profound deficits in aversive memory formation. Atomoxetine, an approved attention-deficit/hyperactivity disorder (ADHD) treatment, ameliorated the hyperactive phenotype. Notably, we identified a patient carrying the I205N variant presenting with ADHD and mild intellectual disability, mirroring the behavioral features observed in I205K KI mice. Additional neurodevelopmental disorder-associated variants within the same hydrophobic pocket similarly disrupted LLPS in vitro. Molecular dynamics simulations revealed these variants destabilize the CaMKII-GluN2B interaction through distinct mechanisms that perturb the dynamic stability of the binding interface. These findings establish CaMKII-mediated phase separation as critical for linking synaptic molecular assembly to cognitive function and provide a unifying molecular basis for synaptic disorganization, hyperactivity, and memory deficits associated with neurodevelopmental disorders. SignificanceCaMKII is essential for synaptic plasticity and memory, yet the contribution of its non-catalytic functions, including liquid-liquid phase separation (LLPS), to brain function remains unclear. Here, we show that disrupting CaMKII LLPS with its synaptic partners impairs synaptic localization, abolishes LTP, and causes profound memory deficits in vivo. A knock-in mouse carrying the I205K mutation showed hyperactivity and impaired learning. This recapitulate the clinical phenotypes of a human patients with the I205N variant, which is associated with ADHD and intellectual disability. Together, these findings establish LLPS as a critical mechanism underlying CaMKII function in the brain and provide a disease-relevant framework for understanding synaptic dysfunction in neurodevelopmental disorders.
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- CaMKII activation triggers persistent formation and segregation of postsynaptic liquid phase
Tomohisa Hosokawa, Pin-Wu Liu, … Yasunori Hayashi·Nature NeurosciencePeer-reviewed·Apr 29, 2021
- Widely used CaMKII regulatory segment mutations cause tight actinin binding and dendritic spine enlargement in unstimulated neurons
Ashton J. Curtis, Jian Zhu, … Matthew G. Gold·Journal of NeurosciencePeer-reviewed·Oct 23, 2025
- CaMKII autophosphorylation but not downstream kinase activity is required for synaptic memory
Xiumin Chen, Qixu Cai, … Roger A. Nicoll·bioRxiv·Aug 25, 2023
- Essential regulatory functions of CaMKII T286 phosphorylation in LTP and two distinct forms of LTD
Sarah G. Cook, Nicole L. Rumian, Karl Ulrich Bayer·bioRxiv·Jan 3, 2022
- Molecular basis of interactions between CaMKII and α-actinin-2 that underlie dendritic spine enlargement
Ashton J. Curtis, Jian Zhu, … Matthew G. Gold·eLifePeer-reviewed·Jul 25, 2023
- The CaMKII D135N mutation blocks kinase activity and reduces GluN2B binding
Matthew E. Larsen, C. Madison Barker, … Karl Ulrich Bayer·Molecular PharmacologyPeer-reviewed·May 1, 2026